Whether early treatment with the BTK inhibitor ibrutinib results in prolonged overall survival (OS) is currently being investigated by the German CLL Study Group in the CLL12 trial [33]. The gene discussed is BTK; the disease is B-cell chronic lymphocytic leukemia.